Purinomia Biotech
Weston, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into Purinomia Biotech
Purinomia is a clinical-stage biotechnology company developing therapeutics for cancer and inflammatory diseases. Its pipeline includes the clinical-stage program PUR001 and three pre-clinical programs (PUR002, PUR003, PUR004).
Founders & leadership
Purinomia Biotech was founded in 2017 by CEO & Scientific Founder, Yan Wu, and Haitao Zhao.
C&
CEO & Scientific FounderCEO & Scientific Founder
YW
Yan WuCEO & Scientific Founder
HZ
Haitao ZhaoScientific Founder
SR
Simon RobsoninScientific FounderHe has held professorships at Harvard University and Beth Israel Deaconess Medical Center since 2007, teaching and conducting research in medicine and anesthesia at Harvard Medical School. Since 2019 he has served as Vice Chair of Research in the Department of Anesthesia, Critical Care and Pain Medicine.
Investors · 1
Reported raises · per SEC filings
Form D private placements$10.3M disclosed across 8 rounds · 2017–2024
▶$1MraisedJun 2024 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Qianye Karen LiuDirector
- Yan Wu ShangExecutive Officer, Director
- Shaoyong HuDirector
- Simon C. RobsonDirector
- Zhe WangExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1M
- Proceeds to insiders
- $200K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedNov 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedNov 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shaoyong HuDirector
- Yan Wu ShangExecutive Officer, Director
- Qianye Karen LiuDirector
- Zhe WangExecutive Officer, Director
- Simon C. RobsonDirector
- Offering amount
- $1M
- Amount sold
- $1M
- Proceeds to insiders
- $100K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Qianye Karen LiuDirector
- Simon C. RobsonDirector
- Zhe WangExecutive Officer, Director
- Shaoyong HuDirector
- Yan Wu ShangExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJan 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJan 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zhe WangExecutive Officer, Director
- Qianye Karen LiuDirector
- Yan Wu ShangExecutive Officer, Director
- Simon C. RobsonDirector
- Shaoyong HuDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Proceeds to insiders
- $300K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedJan 2022 · 2 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJan 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Qianye Karen LiuDirector
- Yan Wu ShangExecutive Officer, Director
- Shaoyong HuDirector
- Simon C. RobsonDirector
- Zhe WangExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.3M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2MraisedFeb 2021 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yan Wu ShangExecutive Officer, Director
- Shaoyong HuDirector
- Zhe WangExecutive Officer, Director
- Qianye Karen LiuDirector
- Simon C. RobsonDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.8MraisedMay 2020 · 3 investors · BiotechnologyRule 506(b)
▶$2.8MraisedMay 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yan Wu ShangExecutive Officer, Director
- Qianye Karen LiuDirector
- Simon C. RobsonDirector
- Shaoyong HuDirector
- Zhe WangExecutive Officer, Director
- Offering amount
- $3.8M
- Amount sold
- $2.8M
- Proceeds to insiders
- $136K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$180KraisedNov 2017 · 1 investors · BiotechnologyRule 506(b)
▶$180KraisedNov 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simon RobsonExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $180K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Purinomia Biotech do?
- Purinomia is a clinical-stage biotechnology company developing therapeutics for cancer and inflammatory diseases. Its pipeline includes the clinical-stage program PUR001 and three pre-clinical programs (PUR002, PUR003, PUR004).
- Who founded Purinomia Biotech?
- Purinomia Biotech was founded by CEO & Scientific Founder, Yan Wu, Haitao Zhao in 2017.
- Who are Purinomia Biotech's investors?
- Purinomia Biotech's investors include BioVentures.
- How much funding has Purinomia Biotech raised?
- Purinomia Biotech has disclosed $10.3M raised across 8 rounds.
- Where is Purinomia Biotech headquartered?
- Purinomia Biotech is headquartered in Weston, US.